WO2002083066A2 - Amino acid complexes of c-aryl glucosides for treatment of diabetes and method - Google Patents
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method Download PDFInfo
- Publication number
- WO2002083066A2 WO2002083066A2 PCT/US2002/011066 US0211066W WO02083066A2 WO 2002083066 A2 WO2002083066 A2 WO 2002083066A2 US 0211066 W US0211066 W US 0211066W WO 02083066 A2 WO02083066 A2 WO 02083066A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- compounds
- inhibitor
- alkyl
- complexes
- Prior art date
Links
- 0 *[C@]([C@@](COCc1ccccc1)OC([C@]1*)=O)[C@]1OCc1ccccc1 Chemical compound *[C@]([C@@](COCc1ccccc1)OC([C@]1*)=O)[C@]1OCc1ccccc1 0.000 description 7
- IFXKITZDCPUFFU-UHFFFAOYSA-N CCc1ccc(Cc2cc(C(C(C3O)O)OC(CO)C3O)ccc2)cc1 Chemical compound CCc1ccc(Cc2cc(C(C(C3O)O)OC(CO)C3O)ccc2)cc1 IFXKITZDCPUFFU-UHFFFAOYSA-N 0.000 description 1
- NUXIUBAETVACSO-ULJHBXBISA-N Cc1ccc(C([C@@H]([C@H]2OCc3ccccc3)OCc3ccccc3)(O)O[C@H](CCOCc3ccccc3)[C@H]2OCc2ccccc2)cc1Cc(cc1)ccc1SC Chemical compound Cc1ccc(C([C@@H]([C@H]2OCc3ccccc3)OCc3ccccc3)(O)O[C@H](CCOCc3ccccc3)[C@H]2OCc2ccccc2)cc1Cc(cc1)ccc1SC NUXIUBAETVACSO-ULJHBXBISA-N 0.000 description 1
- BSKVSBQBZIEYEY-UHFFFAOYSA-N NCC1=CC=[I]C=C1 Chemical compound NCC1=CC=[I]C=C1 BSKVSBQBZIEYEY-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N N[C@@H](Cc1ccccc1)C(O)=O Chemical compound N[C@@H](Cc1ccccc1)C(O)=O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- RVANSNJDRVKJIQ-VEWVWOIWSA-N OC([C@@H]([C@H]1OCc2ccccc2)OCc2ccccc2)(c2cccc(Cc3ccccc3)c2)O[C@H](COCc2ccccc2)[C@H]1OCc1ccccc1 Chemical compound OC([C@@H]([C@H]1OCc2ccccc2)OCc2ccccc2)(c2cccc(Cc3ccccc3)c2)O[C@H](COCc2ccccc2)[C@H]1OCc1ccccc1 RVANSNJDRVKJIQ-VEWVWOIWSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N OC([C@H]1NCCC1)=O Chemical compound OC([C@H]1NCCC1)=O ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
Definitions
- Type II diabetes Approximately 100 million people worldwide suffer • from type II diabetes (NIDDM) , which is characterized by hyperglycemia due to excessive hepatic glucose production and peripheral insulin resistance, the root causes for which are as yet unknown. Hyperglycemia is considered to be the major risk factor for the development of diabetic complications, and is likely to contribute directly to the impairment of insulin secretion seen in advanced NIDDM. Normalization of plasma glucose in NIDDM patients would be predicted to improve insulin action, and to offset the development of diabetic complications. An inhibitor of the sodium-dependent glucose transporter SGLT2 in the kidney is expected to aid in the normalization of plasma glucose levels, and perhaps body weight, by enhancing glucose excretion. Hyperglycemia is a hallmark of type II diabetes
- the instant invention provides a process for producing crystalline 2:1 or 1:1 complexes between either the (D) or (L) enantiomer of natural amino acids and amorphous C-aryl glucoside compounds of formula I wherein
- R ' R 2 and R 2a are independently hydrogen, OH, OR 5 , alkyl, -OCHF 2 , -0CF 3 , -SR 5 or halogen;
- R and R are independently hydrogen, OH, OR 5b , alkyl, cycloalkyl, CF 3 , -OCHF 2 , -OCF 3 , halogen, -CONR 6 R 6a , -C0 2 R 5c , -C0 2 H, -COR 6b , -CH(0H)R 5c , -CH(OR 5d )R 6d , -CN, -NHC0R 5e , -NHS0 2 R 5f , -NHS0 2 Aryl, -SR 5g , -SOR 5h , -S0 2 R 5i , -S0 2 Aryl, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, 0, S, SO, and/or S0 2 , or R 3 and R 4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or
- R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h and R 5i are independently alkyl;
- the instant invention provides a means to convert compounds of formula I from viscous oils and amorphous solids to tractible crystalline solids that can be 1) conveniently isolated and transferred, 2) recrystallized to constant reproducible purity, and 3) formulated to provide pharmaceutical compositions that can be administered as tablets or in solution for treating or delaying the progression or onset of diabetes, especially type I and type II diabetes, including complications of diabetes, including retinopathy, neuropathy, nephropathy and delayed wound healing, and related diseases such as insulin resistance (impaired glucose homeostasis) , hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, hyperlipidemia including hypertriglyceridemia, Syndrome X, atherosclerosis and hypertension, and for increasing high density lipoprotein levels, wherein a therapeutically effective amount of a compound of formula I as an amino acid complex is administered to a human patient in need of treatment.
- insulin resistance paired glucose homeostasis
- hyperglycemia hyperinsulinemia
- a method for treating diabetes and related diseases as defined above and hereinafter wherein a therapeutically effective amount of a combination of a complex of either the (D) or (L) enantiomer of natural amino acids with a compound of structure I and another type of antidiabetic agent and/or another type of therapeutic agent such as a hypolipidemic agent is administered to a human patient in need of treatment .
- R 1 is hydrogen, halogen, lower alkoxy, or lower alkyl and R 4 is lower alkyl, R 5a O, -OCHF 2 , -SR 5g , -SOR 5h , -S0 2 R 5i , or OH. It is preferred that R 1 be linked para to the glucoside bond and the R 4 substituent be linked at the para position.
- compounds of formula I can be prepared by treatment of compounds of formula II with a Lewis acid such BBr 3 , BC1 3 , or BCl 3 -Me 2 S in a solvent such as CH 2 C1 2 at -78°.
- a solvent such as EtSH containing BF 3 -Et 2 0, at 20°.
- silanes such as Et 3 SiH in a solvent such as MeCN or CH 2 C1 2 containing a Lewis acid such as BF 3 -Et 2 0 or TFA at -30° to +60°.
- Compounds ( of formula I where R 4 is CH(OR 5h )R 6d can be prepared by treatment of compounds of formula I where R 4 is COR 6b sequentially with 1) an acetylating agent such as Ac 2 0 in a solvent such as pyridine alone or CH 2 C1 2 containing 1.5 equivalents of a base such as Et 3 N, 2) a reducing agent such as NaBH 4 in a solvent such as EtOH, 3) an alkylating agent such as R 5h Br or R 5h I in the presence of a base such as NAH in a solvent such as DMF, and 4) alkaline ester hydrolysis conditions such as LiOH in a 2:3:1 mixture of THF/MeOH/H 2 0.
- an acetylating agent such as Ac 2 0 in a solvent such as pyridine alone or CH 2 C1 2 containing 1.5 equivalents of a base such as Et 3 N
- a reducing agent such as NaBH 4 in a solvent such as EtOH
- a reducing agent such as Et 3 SiH in a solvent such as MeCN or CH 2 C1 2 or mixtures thereof containing a catalyst such as BF 3 -Et 2 0.
- silanes such as Et 3 SiH or i-Pr 3 SiH in a solvent such as MeCN containing a Lewis acid such as BF 3 -Et 2 0 at -30°.
- lower alkyl as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons containing 1 to 8 carbons
- alkyl and alk as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4- dimethylpentyl, octyl, 2, 2, 4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents such as halo, for example F, Br
- cycloalkyl as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,
- any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio and/or any of the alkyl substituents.
- substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio and/or any of the alkyl substituents.
- alkanoyl as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.
- lower alkenyl as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 8 carbons
- alkenyl as used herein by itself or as part of another group refers to straight or branched chain redicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 2 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-do
- lower alkynyl refers to straight or branched chain radicals of 2 to 8 carbons
- alkynyl refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4- pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4- decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4
- arylakyl alkyl, alkenyl and alkynyl groups as described above having an aryl substituent.
- alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed “alkylene” groups and may optionally be substituted as defined above for “alkyl”.
- alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed “alkenylene groups” and “alkynylene groups”, respectively, and may optionally be substituted as defined above for “alkenyl” and “alkynyl”.
- Suitable alkylene, alkenylene or alkynylene groups (CH 2 ) m or (CH 2 ) P (where p is 1 to 8, preferably 1 to 5, and m is 1 to 5, preferably 1 to 3, which includes alkylene, alkenylene or alkynylene groups) as defined herein, may optionally include 1, 2, or 3 substituents which include alkyl, alkenyl, halogen, cyano, hydroxy, alkoxy, amino, thioalkyl, keto, C 3 -C ⁇ cycloalkyl, alkylcarbonylamino or alkylcarbonyloxy.
- Examples of (CH 2 ) m or (CH 2 ) P , alkylene, alkenylene and alkynylene include -CH 2 - , -CH 2 CH 2 - ,
- heteroaryl refers to a 5- or 6- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g., benzothiophenyl or indolyl) , and includes possible N-oxides.
- the heteroaryl group may optionally include 1 to 4 substituents such as any of the the alkyl substituents set out above. Examples of heteroaryl groups include the following:
- rosiglitazone SKB
- pioglitazone Takeda
- Mitsubishi's MCC-555 Dislosed in U.S. Patent No. 5,594,016
- Glaxo-Welcome ' s GL-262570 englitazone
- CP- 68722, Pfizer englitazone
- darglitazone CP-86325, Pfizer
- isaglitazone MIT/J&J
- JTT-501 JPNT/P&U
- L-895645 Merck
- R-119702 Sankyo/WL
- NN-2344 Dr. Reddy/NN
- YM-440 Yamanouchi
- squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ- PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc, 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.
- the 'dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.
- a preferred oral dosage form such as tablets or capsules, will contain the MTP inhibitor in an amount of from about 1 to about 500 mg, preferably from about 2 to about 400 mg, and more preferably from about 5 to about 250 mg, one to four times daily.
- the beta 3 adrenergic agonist which may be optionally employed in combination with complexes of either the (D) or (L) enantiomer of natural amino acids with compounds of formula I may be AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, with AJ9677, L750,355 and CP331648 being preferred.
- the thyroid receptor beta compound which may be optionally employed in combination with complexes of either the (D) or (L) enantiomer of natural amino acids with compounds of formula I may be a thyroid receptor ligand as disclosed in W097/21993 (U. Cal SF) , WO99/00353 (KaroBio) and GB98/284425 (KaroBio) , with compounds of the KaroBio applications being preferred.
- the anorectic agent which may be optionally employed in combination with complexes of either the (D) or (L) enantiomer of natural amino acids with compounds of formula I may be dexamphetamine, phentermine, phenylpropanolamine or mazindol, with dexamphetamine being preferred.
- the various anti-obesity agents described above may be employed in the same dosage form with complexes of either the (D) or (L) enantiomer of natural amino acids with compounds of formula I or in different dosage forms, in dosages and regimens as generally known in the art or in the PDR.
- anti-platelet agent examples include abciximab, ticlopidine, eptifibatide, dipyridamole, aspirin, anagrelide, tirofiban and/or clopidogrel.
- EtOAc/hexane eluted nonpolar impurities; 1:3 EtOAc/hexane eluted the desired beta C-arylglucoside (23g) which formed a white solid upon isolation.
- the desired product (poorly soluble in iPrOH) formed a third phase intermediate in density between the iPrOH and aq layer (pH ⁇ 8 with precipitated salts)
- the iPrOH layer was separated and the volatiles removed using a rotary evaporater. Both this residue and the oily product layer were dissolved in EtOAc. After three EtOAc extractions of the aqueous layer, the combined EtOAc layers were washed with brine, dried over NaS0 4 prior to removal of the volatiles. By HPLC, the conversion of phenol to desired product was 95%.
- the crude product was purified by chromatography using 1:7 EtOAc to elute 18g of the tetrabenzylated difluoromethyl ether.
- Part I compound 1 prepared by dissolution in 0.3 mL of ethanol upon heating to 55°, was transferred to a stirred 50° solution comprised of (L) -phenylalanine (22 mg, 0.13 mmol) in 0.9 mL H 2 0. After mixing was complete, stirring was stopped and the solution was allowed to cool to 20° over 6 hr. (Seed crystals can be added to aid crystal formation.) After 24 hr small white needles were isolated by filtration, washed 3x with cold 25% ethanol/H 2 0, and air dried.
- Copious gas began to evolve as the reaction progressively became homogeneous when stirred for 3 hr. (Warming to ⁇ 35° accelerates this process.) Filtration through a glass frit to remove of any residual solid and subsequent concentration using a rotary evaporator yielded the desired acid chloride as a viscous golden oil.
- Part E compound 3 prepared by dissolution in 7 mL of ethanol upon heating to 60°, was quickly transferred to a stirred 80° solution comprised of (L) -phenylalanine (2.23 g, 0.13 mmol) and 89.2 mL of H 2 0. After mixing was complete, stirring was continued at 80° until the solution was clear. The stirred solution was cooled to ⁇ 60° over ⁇ 10 min whereupon a milky white suspension began to form. Upon each 2° drop in temperature, seed crystals were added in small amounts to promote crystalization which normally began at 52°. The suspension was then cooled to 40° and stirred for 4 hr.
- Seed crystals for the 1:1 proline/glucoside complex were prepared by stirring the 2:1 proline/glucoside complex (300 mg ) described in Example 5 in MeOH (1 mL) for 72 hr at 20°. The resulting slurry was filtered using centrifugation to provide a solid with m.p. of 162- 163°.
- Anisotropically refined atoms are given in the form of the isotropic equivalent displacement parameter defined as:
- anisotrop ⁇ displacement parameter is : exp [-2PI2(h2a2 ⁇ (l,D + 2b2 ⁇ (2,2) + 12c20(3,3) + 2hkab ⁇ (l,2) + 2hlac ⁇ (l,3)
- Atom x y z B (A2) H Hllll - -00..009911 -0.037 0.249 3.9*
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200230303T SI1385856T1 (en) | 2001-04-11 | 2002-04-08 | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
AU2002254567A AU2002254567B2 (en) | 2001-04-11 | 2002-04-08 | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
CA002444481A CA2444481A1 (en) | 2001-04-11 | 2002-04-08 | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
HU0600232A HUP0600232A2 (en) | 2001-04-11 | 2002-04-08 | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
EP02723801A EP1385856B1 (en) | 2001-04-11 | 2002-04-08 | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
DE60209343T DE60209343T2 (en) | 2001-04-11 | 2002-04-08 | AMINO ACID COMPLEXES OF C-ARYL GLYCOSIDES FOR THE TREATMENT OF DIABETES AND METHODS |
JP2002580871A JP2004536047A (en) | 2001-04-11 | 2002-04-08 | Amino acid conjugates and methods of C-aryl glucosides for treating diabetes |
CY20061100657T CY1105038T1 (en) | 2001-04-11 | 2006-05-19 | AMINO ACID COMPLEXES OF C-ARYL GLYCOSIDES FOR THE THERAPEUTIC TREATMENT OF DIABETES AND METHOD |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28309701P | 2001-04-11 | 2001-04-11 | |
US60/283,097 | 2001-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002083066A2 true WO2002083066A2 (en) | 2002-10-24 |
WO2002083066A3 WO2002083066A3 (en) | 2003-03-06 |
Family
ID=23084500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/011066 WO2002083066A2 (en) | 2001-04-11 | 2002-04-08 | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
Country Status (12)
Country | Link |
---|---|
US (1) | US6774112B2 (en) |
EP (1) | EP1385856B1 (en) |
JP (1) | JP2004536047A (en) |
AT (1) | ATE318272T1 (en) |
AU (1) | AU2002254567B2 (en) |
CA (1) | CA2444481A1 (en) |
CY (1) | CY1105038T1 (en) |
DE (1) | DE60209343T2 (en) |
DK (1) | DK1385856T3 (en) |
ES (1) | ES2258141T3 (en) |
HU (1) | HUP0600232A2 (en) |
WO (1) | WO2002083066A2 (en) |
Cited By (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004013118A1 (en) * | 2002-08-05 | 2004-02-12 | Yamanouchi Pharmaceutical Co., Ltd. | Azulene derivatives and salts thereof |
WO2005092877A1 (en) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
WO2006002912A1 (en) * | 2004-07-06 | 2006-01-12 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyls, medicaments containing said compounds, the use thereof, and methods for producing the same |
WO2006008038A1 (en) * | 2004-07-17 | 2006-01-26 | Boehringer Ingelheim International Gmbh | Methylidene-d-xylopyranosyl-substituted and oxo-d-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and method for the production thereof |
WO2006011502A1 (en) * | 2004-07-27 | 2006-02-02 | Chugai Seiyaku Kabushiki Kaisha | Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
WO2006037537A2 (en) * | 2004-10-01 | 2006-04-13 | Boehringer Ingelheim International Gmbh | D-pyranosyl-substituted phenyls, medicaments containing said compounds, use thereof, and method for the production thereof |
JP2006514649A (en) * | 2003-12-17 | 2006-05-11 | アミリン・ファーマシューティカルズ,インコーポレイテッド | Composition for the treatment and prevention of nephropathy |
WO2006064033A2 (en) * | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7094764B2 (en) | 2003-08-01 | 2006-08-22 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides |
US7094763B2 (en) | 2003-08-01 | 2006-08-22 | Janssen Pharaceutica, N.V. | Substituted fused heterocyclic C-glycosides |
WO2006089872A1 (en) * | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
US7129220B2 (en) | 2003-08-01 | 2006-10-31 | Janssen Pharmaceutica N.V | Substituted indole-O-glucosides |
WO2006120208A1 (en) * | 2005-05-10 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
WO2007028814A1 (en) * | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
EP1783122A1 (en) * | 2004-07-08 | 2007-05-09 | Astellas Pharma Inc. | Process for production of azulene derivatives and intermediates for the synthesis of the same |
WO2007093610A1 (en) | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
WO2007128761A2 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Uses of dpp-iv inhibitors |
WO2008002824A1 (en) * | 2006-06-28 | 2008-01-03 | Bristol-Myers Squibb Company | Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
WO2008013277A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Fused ring spiroketal derivative and use thereof as drug for treating diabetes |
WO2008013280A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Substituted spiroketal derivative and use thereof as drug for treating diabetes |
JP2008508213A (en) * | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | D-glucopyranosyl-phenyl-substituted cyclics, pharmaceuticals containing such compounds, their use and methods for their production |
WO2008044762A1 (en) | 2006-10-13 | 2008-04-17 | Chugai Seiyaku Kabushiki Kaisha | Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
EP1581246A4 (en) * | 2003-12-17 | 2008-04-23 | Amylin Pharmaceuticals Inc | Compositions for the treatment and prevention of nephropathy |
US7375213B2 (en) | 2003-01-03 | 2008-05-20 | Bristol-Myers Squibb Company | Methods of producing C-aryl glucoside SGLT2 inhibitors |
WO2008144346A2 (en) * | 2007-05-18 | 2008-11-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for their preparation |
US7511021B2 (en) | 2003-08-01 | 2009-03-31 | Janssen Pharmaceutica N.V. | Substituted indazole-O-glucosides |
US7589193B2 (en) | 2004-09-23 | 2009-09-15 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
JP2010504300A (en) * | 2006-09-21 | 2010-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, pharmaceuticals containing the compounds and methods of use and preparation thereof |
US7662790B2 (en) | 2005-04-15 | 2010-02-16 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7666845B2 (en) | 2006-12-04 | 2010-02-23 | Janssen Pharmaceutica N.V. | Compounds having inhibitory activity against sodium-dependent glucose transporter |
US7683160B2 (en) | 2005-08-30 | 2010-03-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7713938B2 (en) | 2005-05-03 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7767651B2 (en) | 2005-01-28 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Spiroketal derivatives and use thereof as diabetic medicine |
US7776830B2 (en) | 2006-05-03 | 2010-08-17 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
EP2226076A1 (en) | 2009-02-25 | 2010-09-08 | Henning Vollert | Plant Extract for the Prophylaxis and Treatment of Hyperglycemic Diseases |
US7838499B2 (en) | 2007-08-23 | 2010-11-23 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
US7847074B2 (en) | 2005-09-15 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof |
US7851617B2 (en) | 2006-07-27 | 2010-12-14 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
US7851602B2 (en) | 2005-07-27 | 2010-12-14 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7935674B2 (en) | 2005-01-31 | 2011-05-03 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
US7943788B2 (en) | 2003-08-01 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
US7943582B2 (en) | 2006-12-04 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
AU2007232763B2 (en) * | 2006-04-05 | 2011-07-28 | Astellas Pharma Inc. | Cocrystal of C-glycoside derivative and L-proline |
CN102167715A (en) * | 2011-03-07 | 2011-08-31 | 上海惠斯生物科技有限公司 | Eutectic preparation method of sodium-glucose cotransporter 2 bulk pharmaceutical chemicals |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8048897B2 (en) | 2004-07-26 | 2011-11-01 | Chugai Seiyaku Kabushiki Kaisha | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
US8129434B2 (en) | 2007-12-13 | 2012-03-06 | Theracos, Inc. | Benzylphenyl cyclohexane derivatives and methods of use |
US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
CN102549005A (en) * | 2009-09-30 | 2012-07-04 | 贝林格尔.英格海姆国际有限公司 | Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
WO2012109996A1 (en) | 2011-02-18 | 2012-08-23 | 上海璎黎科技有限公司 | Aryl glycoside compound, preparation method and use thereof |
US8283454B2 (en) | 2008-08-22 | 2012-10-09 | Theracos, Inc. | Processes for the preparation of SGLT2 inhibitors |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
JP2012207037A (en) * | 2002-05-20 | 2012-10-25 | Bristol Myers Squibb Co | C-aryl glucoside sglt2 inhibitor and method |
US8389473B2 (en) | 2002-12-17 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Treatment of cardiac arrhythmias |
EP2604612A1 (en) * | 2010-08-10 | 2013-06-19 | Shanghai Hengrui Pharmaceutical Co. Ltd. | C-aryl glucoside derivatives, preparation rpocess and pharmaceutical use thereof |
CN103319445A (en) * | 2007-12-27 | 2013-09-25 | 百时美施贵宝公司 | Crystal structure of SGLT2 inhibitor and preparation method of crystal structure |
US8551957B2 (en) | 2007-08-16 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
EP2679229A1 (en) | 2012-06-30 | 2014-01-01 | BioActive Food GmbH | Composition for the treatment of hyperglycemic diseases |
WO2014101865A1 (en) | 2012-12-31 | 2014-07-03 | 上海璎黎科技有限公司 | Composition of glucose derivative and proline, crystal, preparation method and application |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
EP2774619A1 (en) | 2013-03-04 | 2014-09-10 | BioActive Food GmbH | Composition for the treatment of hyperglycaemic diseases |
CN104059042A (en) * | 2013-03-22 | 2014-09-24 | 正大天晴药业集团股份有限公司 | C-triaryl glucoside SGLT-2 inhibitor |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
US8945582B2 (en) | 2006-09-07 | 2015-02-03 | Glaxosmithkline Biologicals S.A. | Vaccine |
CN104387354A (en) * | 2007-12-27 | 2015-03-04 | 阿斯利康公司 | Crystal structures and preparation methods of SGLT2 inhibitors |
US8987323B2 (en) | 2010-06-12 | 2015-03-24 | Theracos, Inc. | Crystalline form of benzylbenzene SGLT2 inhibitor |
US9024010B2 (en) | 2009-09-30 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US9024009B2 (en) | 2007-09-10 | 2015-05-05 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
CN104788438A (en) * | 2015-05-04 | 2015-07-22 | 南京华威医药科技开发有限公司 | B crystal form of empagliflozin and preparation of B crystal form |
US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
US9174971B2 (en) | 2009-10-14 | 2015-11-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
EP2944311A1 (en) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Combination of biologically active substances for treating hyperglycemic diseases |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AU2014268177B2 (en) * | 2006-06-28 | 2016-05-19 | Astrazeneca Ab | Crystalline solvates and complexes of (1s) -1, 5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
CN103254119B (en) * | 2007-07-10 | 2016-07-06 | 莱西肯医药有限公司 | Inhibitor of sodium glucose co-transporter 2 white 2 and usage thereof |
US9464043B2 (en) | 2013-10-12 | 2016-10-11 | Theracos Sub, Llc | Preparation of hydroxy-benzylbenzene derivatives |
WO2016161995A1 (en) | 2015-04-08 | 2016-10-13 | Zentiva, K.S. | Solid forms of amorphous dapagliflozin |
KR20160132120A (en) * | 2014-04-01 | 2016-11-16 | 베링거잉겔하임베트메디카게엠베하 | Treatment of metabolic disorders in equine animals |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2017046730A1 (en) | 2015-09-15 | 2017-03-23 | Laurus Labs Private Limited | Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
WO2017060925A1 (en) * | 2015-10-09 | 2017-04-13 | Harman Finochem Limited | Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof |
ITUB20156048A1 (en) * | 2015-12-01 | 2017-06-01 | Dipharma Francis Srl | CO-CRYSTAL AND AMORPHOUS FORM OF AN ANTI-DIABETIC DRUG |
US9914724B2 (en) | 2014-04-14 | 2018-03-13 | Shanghai De Novo Pharmatech Co., Ltd. | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10220017B2 (en) | 2015-08-27 | 2019-03-05 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10544135B2 (en) | 2011-04-13 | 2020-01-28 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US10555958B2 (en) | 2014-09-25 | 2020-02-11 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
EP2139494B1 (en) | 2007-03-22 | 2020-03-11 | AstraZeneca AB | Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate |
US10603300B2 (en) | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US10617668B2 (en) | 2010-05-11 | 2020-04-14 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
US10617666B2 (en) | 2013-12-17 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
US10864225B2 (en) | 2013-04-04 | 2020-12-15 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
US11096918B2 (en) | 2005-11-09 | 2021-08-24 | Novartis Pharmaceuticals Corporation | Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations |
US11207337B2 (en) | 2015-09-15 | 2021-12-28 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2022208172A1 (en) | 2021-04-01 | 2022-10-06 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
US11576894B2 (en) | 2009-07-08 | 2023-02-14 | Janssen Pharmaceutica Nv | Combination therapy for the treatment of diabetes |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
DE602005025755D1 (en) | 2004-06-04 | 2011-02-17 | Teva Pharma | IRBESARTAN PHARMACEUTICAL COMPOSITION CONTAINING |
DE602005024413D1 (en) | 2004-08-20 | 2010-12-09 | Mannkind Corp | CATALYSIS OF DIKETOPIPERAZINE SYNTHESIS |
ES2540886T3 (en) | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Dicetopiperazine salts for drug administration |
AR053329A1 (en) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | INDOL DERIVATIVES USEFUL AS INHIBITORS OF GLUCOSE CONVEYORS DEPENDENT ON SODIUM (SGLT) |
CN101277949A (en) * | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | Dipeptidyl peptidase-iv inhibitors |
WO2007000445A1 (en) * | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
KR101557502B1 (en) | 2005-09-14 | 2015-10-06 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of active agents for crystalline micropaticle surfaces |
AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
TWI499414B (en) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
PT2183263E (en) * | 2007-07-26 | 2012-01-11 | Lexicon Pharmaceuticals Inc | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
ES2547529T3 (en) * | 2007-10-24 | 2015-10-07 | Mannkind Corporation | Inhalable dry powder formulation comprising GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration |
JP5498392B2 (en) * | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1,5-Dihydro-pyrazolo [3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators for the treatment of CNS disorders |
JP5302900B2 (en) * | 2008-01-31 | 2013-10-02 | アステラス製薬株式会社 | Pharmaceutical composition for the treatment of fatty liver disease |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
CA2725047A1 (en) | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
PL2293833T3 (en) | 2008-06-13 | 2016-08-31 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
TWI532497B (en) | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
RS52236B (en) * | 2008-08-28 | 2012-10-31 | Pfizer Inc. | Dioxa-bicyclo(3.2.1)octane-2,3,4-triol derivatives |
NZ590788A (en) | 2008-09-08 | 2012-11-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of cns disorders |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2395968B1 (en) * | 2009-02-13 | 2024-01-17 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient |
JP5896276B2 (en) * | 2009-02-13 | 2016-03-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | SGLT-2 inhibitor for the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or hyperglycemia |
EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
MX2011010184A (en) * | 2009-03-31 | 2011-10-28 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators. |
CA2755392A1 (en) * | 2009-04-16 | 2010-10-21 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical compositions with (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1thio-d-glucitol and an insulin secretagogue |
KR20180079458A (en) | 2009-06-12 | 2018-07-10 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
WO2011003976A1 (en) | 2009-07-10 | 2011-01-13 | Janssen Pharmaceutica Nv | CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE |
AR077859A1 (en) * | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS |
ES2527179T3 (en) | 2009-11-02 | 2015-01-21 | Pfizer Inc. | Dioxa-bicyclo derivatives [3.2.1] octane-2,3,4-triol |
US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
CA2801936C (en) | 2010-06-21 | 2021-06-01 | Mannkind Corporation | Dry powder drug delivery system and methods |
CN105541849B (en) | 2010-08-12 | 2018-03-23 | 勃林格殷格翰国际有限公司 | The ketone derivatives of the dihydro-pyrazolo of 6 cycloalkyl 1,5 [3,4 d] pyrimidine 4 and its purposes as PDE9A inhibitor |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
EP2694402B1 (en) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
JP2014530186A (en) | 2011-09-13 | 2014-11-17 | パナセア バイオテック リミテッド | Novel SGLT inhibitor |
EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
WO2013064909A2 (en) * | 2011-10-31 | 2013-05-10 | Scinopharm Taiwan, Ltd. | Crystalline and non-crystalline forms of sglt2 inhibitors |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
KR102499439B1 (en) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
MX2020009878A (en) | 2013-07-18 | 2022-07-27 | Mannkind Corp | Heat-stable dry powder pharmaceutical compositions and methods. |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
EP3142661B1 (en) * | 2014-05-16 | 2021-10-06 | Astrazeneca AB | Method for suppressing glucagon secretion of an sglt2 inhibitor |
WO2015198227A1 (en) | 2014-06-23 | 2015-12-30 | Sun Pharmaceutical Industries Limited | Co-crystal of dapagliflozin with citric acid |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
WO2017141202A1 (en) | 2016-02-17 | 2017-08-24 | Lupin Limited | Complex of sglt2 inhibitor and process for preparation thereof |
US10793588B2 (en) | 2016-05-28 | 2020-10-06 | Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd. | Crystal form of sodium-glucose cotransporter 2 inhibitor |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
CN108239055B (en) * | 2016-12-23 | 2023-07-18 | 杭州领业医药科技有限公司 | THR 1442L-aspartic acid eutectic crystal, preparation method and pharmaceutical composition thereof |
EP3823631A1 (en) | 2018-07-19 | 2021-05-26 | Astrazeneca AB | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
SG11202102498UA (en) * | 2018-09-26 | 2021-04-29 | Lexicon Pharmaceuticals Inc | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
CN113149828A (en) * | 2021-03-31 | 2021-07-23 | 山东寿光增瑞化工有限公司 | Preparation method of 5-bromo-2-methylbenzoic acid |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5444050A (en) * | 1994-04-29 | 1995-08-22 | Texas Biotechnology Corporation | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa |
US5663377A (en) * | 1992-11-13 | 1997-09-02 | The Ohio State Research Foundation | C-glycoside analogues of N-(4-hydroxyphenyl) retinamide-O-glucuronide |
WO1998031697A1 (en) * | 1997-01-15 | 1998-07-23 | Sankyo Company, Limited | Aryl c-glycoside compounds and sulfated esters thereof |
WO2001016147A1 (en) * | 1999-08-31 | 2001-03-08 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (en) | 1974-06-07 | 1981-03-18 | ||
NO154918C (en) | 1977-08-27 | 1987-01-14 | Bayer Ag | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (en) | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
JPS6051189A (en) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | Thiazolidine derivative and its preparation |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
DE3581638D1 (en) | 1984-12-04 | 1991-03-07 | Sandoz Ag | INDEN ANALOGA BY MEVALONOLAKTON AND THEIR DERIVATIVES. |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
KR900001212B1 (en) | 1985-10-25 | 1990-02-28 | 산도즈 파마슈티칼스 코오포레이숀 | Mevalonolactones and their derivatives and process and pharmaceutical use, thereof |
DE3543999A1 (en) | 1985-12-13 | 1987-06-19 | Bayer Ag | HIGH PURITY ACARBOSE |
FR2596393B1 (en) | 1986-04-01 | 1988-06-03 | Sanofi Sa | HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
GB2205837B (en) | 1987-05-22 | 1991-11-20 | Squibb & Sons Inc | Phosphorus-containing hmg-coa reductase inhibitors |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (en) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | Quinoline mevalonolactones |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (en) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (en) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
DK36392D0 (en) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | USE OF CHEMICAL COMPOUND |
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
DK0680320T3 (en) | 1993-01-19 | 1999-10-25 | Warner Lambert Co | Stable oral CI-981 preparation and method of preparation thereof |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
EP0873361B1 (en) | 1995-12-13 | 2006-11-02 | The Regents Of The University Of California | Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
EP1062222A1 (en) | 1998-03-09 | 2000-12-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
DE19823831A1 (en) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
DE19828113A1 (en) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs of Dipeptidyl Peptidase IV Inhibitors |
DE19828114A1 (en) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs of unstable inhibitors of dipeptidyl peptidase IV |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
-
2002
- 2002-04-08 HU HU0600232A patent/HUP0600232A2/en unknown
- 2002-04-08 JP JP2002580871A patent/JP2004536047A/en active Pending
- 2002-04-08 AU AU2002254567A patent/AU2002254567B2/en not_active Ceased
- 2002-04-08 US US10/117,914 patent/US6774112B2/en not_active Expired - Lifetime
- 2002-04-08 DE DE60209343T patent/DE60209343T2/en not_active Expired - Fee Related
- 2002-04-08 WO PCT/US2002/011066 patent/WO2002083066A2/en active IP Right Grant
- 2002-04-08 CA CA002444481A patent/CA2444481A1/en not_active Abandoned
- 2002-04-08 AT AT02723801T patent/ATE318272T1/en not_active IP Right Cessation
- 2002-04-08 EP EP02723801A patent/EP1385856B1/en not_active Expired - Lifetime
- 2002-04-08 ES ES02723801T patent/ES2258141T3/en not_active Expired - Lifetime
- 2002-04-08 DK DK02723801T patent/DK1385856T3/en active
-
2006
- 2006-05-19 CY CY20061100657T patent/CY1105038T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663377A (en) * | 1992-11-13 | 1997-09-02 | The Ohio State Research Foundation | C-glycoside analogues of N-(4-hydroxyphenyl) retinamide-O-glucuronide |
US5444050A (en) * | 1994-04-29 | 1995-08-22 | Texas Biotechnology Corporation | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa |
WO1998031697A1 (en) * | 1997-01-15 | 1998-07-23 | Sankyo Company, Limited | Aryl c-glycoside compounds and sulfated esters thereof |
WO2001016147A1 (en) * | 1999-08-31 | 2001-03-08 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP1385856A2 * |
Cited By (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012207037A (en) * | 2002-05-20 | 2012-10-25 | Bristol Myers Squibb Co | C-aryl glucoside sglt2 inhibitor and method |
US7169761B2 (en) | 2002-08-05 | 2007-01-30 | Astellas Pharma Inc. | Azulene derivatives and salts thereof |
WO2004013118A1 (en) * | 2002-08-05 | 2004-02-12 | Yamanouchi Pharmaceutical Co., Ltd. | Azulene derivatives and salts thereof |
US8389473B2 (en) | 2002-12-17 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Treatment of cardiac arrhythmias |
US7932379B2 (en) | 2003-01-03 | 2011-04-26 | Bristol-Myers Squibb Company | Methods of producing C-aryl glucoside SGLT2 inhibitors |
US7375213B2 (en) | 2003-01-03 | 2008-05-20 | Bristol-Myers Squibb Company | Methods of producing C-aryl glucoside SGLT2 inhibitors |
US7129220B2 (en) | 2003-08-01 | 2006-10-31 | Janssen Pharmaceutica N.V | Substituted indole-O-glucosides |
US7482330B2 (en) | 2003-08-01 | 2009-01-27 | Janssen Pharmaceutica N.V. | Substituted fused heterocyclic C-glycosides |
US7094764B2 (en) | 2003-08-01 | 2006-08-22 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides |
US7094763B2 (en) | 2003-08-01 | 2006-08-22 | Janssen Pharaceutica, N.V. | Substituted fused heterocyclic C-glycosides |
US8202984B2 (en) | 2003-08-01 | 2012-06-19 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
US8222219B2 (en) | 2003-08-01 | 2012-07-17 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
US7511020B2 (en) | 2003-08-01 | 2009-03-31 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
US7511021B2 (en) | 2003-08-01 | 2009-03-31 | Janssen Pharmaceutica N.V. | Substituted indazole-O-glucosides |
US7943788B2 (en) | 2003-08-01 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
US7816330B2 (en) | 2003-08-01 | 2010-10-19 | Janssen Pharmaceutica Nv | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
CN103214471A (en) * | 2003-08-01 | 2013-07-24 | 田边三菱制药株式会社 | Novel compound |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
EP1581246A4 (en) * | 2003-12-17 | 2008-04-23 | Amylin Pharmaceuticals Inc | Compositions for the treatment and prevention of nephropathy |
JP2006514649A (en) * | 2003-12-17 | 2006-05-11 | アミリン・ファーマシューティカルズ,インコーポレイテッド | Composition for the treatment and prevention of nephropathy |
EP2360164A2 (en) | 2004-03-16 | 2011-08-24 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
EP2360164A3 (en) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
EP2360165A2 (en) | 2004-03-16 | 2011-08-24 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7579449B2 (en) | 2004-03-16 | 2009-08-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
EP2295422A3 (en) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production |
CN103435581B (en) * | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | The phenyl derivatives that glucopyranosyl replaces, medicine, its purposes and manufacture method thereof containing this compound |
CN103450129A (en) * | 2004-03-16 | 2013-12-18 | 贝林格尔.英格海姆国际有限公司 | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
EP2295422A2 (en) | 2004-03-16 | 2011-03-16 | Boehringer Ingelheim International GmbH | Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production |
WO2005092877A1 (en) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
EP2360165A3 (en) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
CN103450129B (en) * | 2004-03-16 | 2015-08-12 | 贝林格尔.英格海姆国际有限公司 | The phenyl derivatives that glucopyranosyl replaces, medicine, its purposes and manufacture method thereof containing this compound |
CN103030617A (en) * | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
CN103467423B (en) * | 2004-03-16 | 2016-03-16 | 贝林格尔.英格海姆国际有限公司 | The phenyl derivatives that glucopyranosyl replaces, medicine, its purposes and manufacture method thereof containing this compound |
EA011158B1 (en) * | 2004-03-16 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2006002912A1 (en) * | 2004-07-06 | 2006-01-12 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyls, medicaments containing said compounds, the use thereof, and methods for producing the same |
JP2008505146A (en) * | 2004-07-06 | 2008-02-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | D-xylopyranosyl-substituted phenyl, drug containing said compound, use thereof, and production method thereof |
EP1783122A4 (en) * | 2004-07-08 | 2008-12-10 | Astellas Pharma Inc | Process for production of azulene derivatives and intermediates for the synthesis of the same |
EP1783122A1 (en) * | 2004-07-08 | 2007-05-09 | Astellas Pharma Inc. | Process for production of azulene derivatives and intermediates for the synthesis of the same |
WO2006008038A1 (en) * | 2004-07-17 | 2006-01-26 | Boehringer Ingelheim International Gmbh | Methylidene-d-xylopyranosyl-substituted and oxo-d-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and method for the production thereof |
US8048897B2 (en) | 2004-07-26 | 2011-11-01 | Chugai Seiyaku Kabushiki Kaisha | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
WO2006011502A1 (en) * | 2004-07-27 | 2006-02-02 | Chugai Seiyaku Kabushiki Kaisha | Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
US7943748B2 (en) | 2004-07-27 | 2011-05-17 | Chugai Seiyaku Kabushiki Kaisha | Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
JP2008508213A (en) * | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | D-glucopyranosyl-phenyl-substituted cyclics, pharmaceuticals containing such compounds, their use and methods for their production |
US7589193B2 (en) | 2004-09-23 | 2009-09-15 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US7419959B2 (en) | 2004-10-01 | 2008-09-02 | Boehringer Ingelheim International, Gmbh | D-pyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2006037537A2 (en) * | 2004-10-01 | 2006-04-13 | Boehringer Ingelheim International Gmbh | D-pyranosyl-substituted phenyls, medicaments containing said compounds, use thereof, and method for the production thereof |
WO2006037537A3 (en) * | 2004-10-01 | 2007-03-08 | Boehringer Ingelheim Int | D-pyranosyl-substituted phenyls, medicaments containing said compounds, use thereof, and method for the production thereof |
WO2006064033A3 (en) * | 2004-12-16 | 2007-04-12 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2006064033A2 (en) * | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7767651B2 (en) | 2005-01-28 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Spiroketal derivatives and use thereof as diabetic medicine |
EP3072897A1 (en) | 2005-01-28 | 2016-09-28 | Chugai Seiyaku Kabushiki Kaisha | Spiroketal derivatives and use thereof as diabetic medicine |
US7935674B2 (en) | 2005-01-31 | 2011-05-03 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
US7772378B2 (en) | 2005-02-23 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
JP2008531520A (en) * | 2005-02-23 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucopyranosyl-substituted ((hetero) arylethynyl-benzyl) -benzene derivatives and their use as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors |
WO2006089872A1 (en) * | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
US7662790B2 (en) | 2005-04-15 | 2010-02-16 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
CN101155794B (en) * | 2005-05-03 | 2011-05-11 | 贝林格尔·英格海姆国际有限公司 | Crystalline form of 1-chloro-4-(ss-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7713938B2 (en) | 2005-05-03 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
AU2006245712B2 (en) * | 2005-05-10 | 2012-07-12 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
KR101378320B1 (en) | 2005-05-10 | 2014-03-27 | 베링거 인겔하임 인터내셔날 게엠베하 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
EA014468B1 (en) * | 2005-05-10 | 2010-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
WO2006120208A1 (en) * | 2005-05-10 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
CN103524468A (en) * | 2005-05-10 | 2014-01-22 | 贝林格尔.英格海姆国际有限公司 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US10442795B2 (en) | 2005-05-10 | 2019-10-15 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
TWI384981B (en) * | 2005-05-10 | 2013-02-11 | Boehringer Ingelheim Int | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
CN103524468B (en) * | 2005-05-10 | 2016-08-17 | 贝林格尔.英格海姆国际有限公司 | Prepare the substituted Benzylbenzene derivatives of glucopyranosyl and the method for intermediate thereof |
US9127034B2 (en) | 2005-05-10 | 2015-09-08 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivates and intermediates therein |
US7851602B2 (en) | 2005-07-27 | 2010-12-14 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7683160B2 (en) | 2005-08-30 | 2010-03-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2007028814A1 (en) * | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
US7847074B2 (en) | 2005-09-15 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof |
US11642329B2 (en) | 2005-11-09 | 2023-05-09 | Novartis Pharmaceuticals Corporation | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations |
US11096918B2 (en) | 2005-11-09 | 2021-08-24 | Novartis Pharmaceuticals Corporation | Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations |
WO2007093610A1 (en) | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
AU2007232763B2 (en) * | 2006-04-05 | 2011-07-28 | Astellas Pharma Inc. | Cocrystal of C-glycoside derivative and L-proline |
US8097592B2 (en) | 2006-04-05 | 2012-01-17 | Astellas Pharma Inc. | Cocrystal of C-glycoside derivative and L-proline |
US8557782B2 (en) | 2006-05-03 | 2013-10-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7776830B2 (en) | 2006-05-03 | 2010-08-17 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
WO2007128761A2 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Uses of dpp-iv inhibitors |
EP2351568A2 (en) | 2006-05-04 | 2011-08-03 | Boehringer Ingelheim International GmbH | Uses of dpp-iv inhibitors |
EA028259B1 (en) * | 2006-06-28 | 2017-10-31 | Астразенека Аб | Crystalline solvate of (1s)-1,5-anhydro-l-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivative with amino acid and process for preparing the same |
EA018229B1 (en) * | 2006-06-28 | 2013-06-28 | Бристол-Маерс Сквибб Компани | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
EP2457918A3 (en) * | 2006-06-28 | 2012-08-29 | Bristol-Myers Squibb Company | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
WO2008002824A1 (en) * | 2006-06-28 | 2008-01-03 | Bristol-Myers Squibb Company | Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
AU2014268177B2 (en) * | 2006-06-28 | 2016-05-19 | Astrazeneca Ab | Crystalline solvates and complexes of (1s) -1, 5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
EA020428B1 (en) * | 2006-06-28 | 2014-11-28 | Астразенека Аб | Crystalline solvates of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives as sglt2 inhibitors for the treatment of diabetes |
NO346828B1 (en) * | 2006-06-28 | 2023-01-23 | Astrazeneca Ab | CRYSTALLINE (S)-PROPYLENE GLYCOL SOLVATE OF 1-C-6-CHLORO-4'-ETHOXYDIPHENYLMETHAN-3-YL-β-D-GLUCOPYRANOSE |
US8501698B2 (en) | 2006-06-28 | 2013-08-06 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
EP3363807B1 (en) | 2006-06-28 | 2019-11-13 | AstraZeneca AB | Pharmaceutical composition comprising crystalline (2s,3r,4s,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol (s)-propylene glycol solvate |
US9453039B2 (en) | 2006-06-28 | 2016-09-27 | Astrazeneca Ab | Crystal structures of SGLT2 inhibitors and processes for preparing same |
EA035999B1 (en) * | 2006-06-28 | 2020-09-10 | Астразенека Аб | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
WO2008013280A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Substituted spiroketal derivative and use thereof as drug for treating diabetes |
US7851617B2 (en) | 2006-07-27 | 2010-12-14 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
WO2008013277A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Fused ring spiroketal derivative and use thereof as drug for treating diabetes |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8956625B2 (en) | 2006-09-07 | 2015-02-17 | Glaxosmithkline Biologicals, S.A. | Inactivated polio vaccines |
US8945582B2 (en) | 2006-09-07 | 2015-02-03 | Glaxosmithkline Biologicals S.A. | Vaccine |
JP2010504300A (en) * | 2006-09-21 | 2010-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, pharmaceuticals containing the compounds and methods of use and preparation thereof |
WO2008044762A1 (en) | 2006-10-13 | 2008-04-17 | Chugai Seiyaku Kabushiki Kaisha | Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US8513202B2 (en) | 2006-12-04 | 2013-08-20 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
US7943582B2 (en) | 2006-12-04 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
US7666845B2 (en) | 2006-12-04 | 2010-02-23 | Janssen Pharmaceutica N.V. | Compounds having inhibitory activity against sodium-dependent glucose transporter |
US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
EP2139494B1 (en) | 2007-03-22 | 2020-03-11 | AstraZeneca AB | Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate |
EP2508188B1 (en) | 2007-03-22 | 2023-05-10 | AstraZeneca AB | Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate |
WO2008144346A2 (en) * | 2007-05-18 | 2008-11-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for their preparation |
WO2008144346A3 (en) * | 2007-05-18 | 2009-01-22 | Bristol Myers Squibb Co | Crystal structures of sglt2 inhibitors and processes for their preparation |
CN103254119B (en) * | 2007-07-10 | 2016-07-06 | 莱西肯医药有限公司 | Inhibitor of sodium glucose co-transporter 2 white 2 and usage thereof |
US8551957B2 (en) | 2007-08-16 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
US7838499B2 (en) | 2007-08-23 | 2010-11-23 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
US8802637B2 (en) | 2007-08-23 | 2014-08-12 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
EP3318562A3 (en) * | 2007-08-23 | 2018-09-12 | Theracos Sub, LLC | Benzylbenzene derivatives and methods of use |
US8575321B2 (en) | 2007-08-23 | 2013-11-05 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
US8106021B2 (en) | 2007-08-23 | 2012-01-31 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
US9024009B2 (en) | 2007-09-10 | 2015-05-05 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US8129434B2 (en) | 2007-12-13 | 2012-03-06 | Theracos, Inc. | Benzylphenyl cyclohexane derivatives and methods of use |
CN104387354A (en) * | 2007-12-27 | 2015-03-04 | 阿斯利康公司 | Crystal structures and preparation methods of SGLT2 inhibitors |
CN103319445A (en) * | 2007-12-27 | 2013-09-25 | 百时美施贵宝公司 | Crystal structure of SGLT2 inhibitor and preparation method of crystal structure |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
US9006403B2 (en) | 2008-08-22 | 2015-04-14 | Theracos, Inc. | Processes for the preparation of SGLT2 inhibitors |
US8283454B2 (en) | 2008-08-22 | 2012-10-09 | Theracos, Inc. | Processes for the preparation of SGLT2 inhibitors |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EP2226076A1 (en) | 2009-02-25 | 2010-09-08 | Henning Vollert | Plant Extract for the Prophylaxis and Treatment of Hyperglycemic Diseases |
US11576894B2 (en) | 2009-07-08 | 2023-02-14 | Janssen Pharmaceutica Nv | Combination therapy for the treatment of diabetes |
US9873714B2 (en) | 2009-09-30 | 2018-01-23 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
CN102549005B (en) * | 2009-09-30 | 2015-08-26 | 贝林格尔.英格海姆国际有限公司 | The preparation method of the crystal formation of the chloro-4-of 1-(β-D-Glucopyranose-1-base)-2-[4-((S)-tetrahydrofuran (THF)-3-base oxygen base)-benzyl]-benzene |
CN102549005A (en) * | 2009-09-30 | 2012-07-04 | 贝林格尔.英格海姆国际有限公司 | Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
US8802842B2 (en) | 2009-09-30 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form |
US9024010B2 (en) | 2009-09-30 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US9174971B2 (en) | 2009-10-14 | 2015-11-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US10617668B2 (en) | 2010-05-11 | 2020-04-14 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
US9834573B2 (en) | 2010-06-12 | 2017-12-05 | Theracos Sub, Llc | Crystalline form of benzylbenzene SGLT2 inhibitor |
US10533032B2 (en) | 2010-06-12 | 2020-01-14 | Theracos Sub, Llc | Crystalline form of benzylbenzene SGLT2 inhibitor |
US8987323B2 (en) | 2010-06-12 | 2015-03-24 | Theracos, Inc. | Crystalline form of benzylbenzene SGLT2 inhibitor |
US10981942B2 (en) | 2010-06-12 | 2021-04-20 | Theracos Sub, Llc | Crystalline form of benzylbenzene SGLT2 inhibitor |
EP2604612A1 (en) * | 2010-08-10 | 2013-06-19 | Shanghai Hengrui Pharmaceutical Co. Ltd. | C-aryl glucoside derivatives, preparation rpocess and pharmaceutical use thereof |
EP2604612A4 (en) * | 2010-08-10 | 2013-07-24 | Shanghai Hengrui Pharm Co Ltd | C-aryl glucoside derivatives, preparation rpocess and pharmaceutical use thereof |
WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
US8980829B2 (en) | 2011-02-18 | 2015-03-17 | Shanghai Yingli Science And Technology Co., Ltd | Aryl glycoside compound, preparation method and use thereof |
WO2012109996A1 (en) | 2011-02-18 | 2012-08-23 | 上海璎黎科技有限公司 | Aryl glycoside compound, preparation method and use thereof |
CN102167715A (en) * | 2011-03-07 | 2011-08-31 | 上海惠斯生物科技有限公司 | Eutectic preparation method of sodium-glucose cotransporter 2 bulk pharmaceutical chemicals |
US10596120B2 (en) | 2011-03-07 | 2020-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US11564886B2 (en) | 2011-03-07 | 2023-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
CN102167715B (en) * | 2011-03-07 | 2013-04-24 | 上海惠斯生物科技有限公司 | Eutectic preparation method of sodium-glucose cotransporter 2 bulk pharmaceutical chemicals |
US10544135B2 (en) | 2011-04-13 | 2020-01-28 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9725478B2 (en) | 2012-04-10 | 2017-08-08 | Theracos Sub, Llc | Process for the preparation of benzylbenzene SGLT2 inhibitors |
EP3549587A1 (en) | 2012-06-30 | 2019-10-09 | BioActive Food GmbH | Composition for the treatment of hyperglycemic diseases |
EP2679229A1 (en) | 2012-06-30 | 2014-01-01 | BioActive Food GmbH | Composition for the treatment of hyperglycemic diseases |
US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
WO2014101865A1 (en) | 2012-12-31 | 2014-07-03 | 上海璎黎科技有限公司 | Composition of glucose derivative and proline, crystal, preparation method and application |
US9738603B2 (en) | 2012-12-31 | 2017-08-22 | Shanghai Yingli Pharmaceutical Co., Ltd. | Complex of glucose derivative and proline, crystal, preparation method and use |
EP2774619A1 (en) | 2013-03-04 | 2014-09-10 | BioActive Food GmbH | Composition for the treatment of hyperglycaemic diseases |
CN104059042A (en) * | 2013-03-22 | 2014-09-24 | 正大天晴药业集团股份有限公司 | C-triaryl glucoside SGLT-2 inhibitor |
CN104059042B (en) * | 2013-03-22 | 2017-02-08 | 正大天晴药业集团股份有限公司 | C-triaryl glucoside SGLT-2 inhibitor |
US10864225B2 (en) | 2013-04-04 | 2020-12-15 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11090323B2 (en) | 2013-04-05 | 2021-08-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10258637B2 (en) | 2013-04-05 | 2019-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11918596B2 (en) | 2013-04-05 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11833166B2 (en) | 2013-04-05 | 2023-12-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10093616B2 (en) | 2013-10-12 | 2018-10-09 | Theracos Sub, Llc | Preparation of hydroxy-benzylbenzene derivatives |
US9464043B2 (en) | 2013-10-12 | 2016-10-11 | Theracos Sub, Llc | Preparation of hydroxy-benzylbenzene derivatives |
US10617666B2 (en) | 2013-12-17 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
US11896574B2 (en) | 2013-12-17 | 2024-02-13 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
US11433045B2 (en) | 2014-01-23 | 2022-09-06 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
US10603300B2 (en) | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
KR102662473B1 (en) * | 2014-04-01 | 2024-05-03 | 베링거잉겔하임베트메디카게엠베하 | Treatment of metabolic disorders in equine animals |
US10688116B2 (en) | 2014-04-01 | 2020-06-23 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
KR20160132120A (en) * | 2014-04-01 | 2016-11-16 | 베링거잉겔하임베트메디카게엠베하 | Treatment of metabolic disorders in equine animals |
US9914724B2 (en) | 2014-04-14 | 2018-03-13 | Shanghai De Novo Pharmatech Co., Ltd. | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof |
EP2944311A1 (en) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Combination of biologically active substances for treating hyperglycemic diseases |
WO2015173383A1 (en) | 2014-05-16 | 2015-11-19 | Bioactive Food Gmbh | Combination of biologically active substances for treatment of hyperglycaemic disorders |
US10555958B2 (en) | 2014-09-25 | 2020-02-11 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
WO2016161995A1 (en) | 2015-04-08 | 2016-10-13 | Zentiva, K.S. | Solid forms of amorphous dapagliflozin |
CN104788438A (en) * | 2015-05-04 | 2015-07-22 | 南京华威医药科技开发有限公司 | B crystal form of empagliflozin and preparation of B crystal form |
US10220017B2 (en) | 2015-08-27 | 2019-03-05 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
US11040961B2 (en) | 2015-09-15 | 2021-06-22 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
US11207337B2 (en) | 2015-09-15 | 2021-12-28 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
US10428053B2 (en) | 2015-09-15 | 2019-10-01 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
WO2017046730A1 (en) | 2015-09-15 | 2017-03-23 | Laurus Labs Private Limited | Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
US10738038B2 (en) | 2015-09-15 | 2020-08-11 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
US10836753B2 (en) | 2015-09-15 | 2020-11-17 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
WO2017060925A1 (en) * | 2015-10-09 | 2017-04-13 | Harman Finochem Limited | Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof |
ITUB20156048A1 (en) * | 2015-12-01 | 2017-06-01 | Dipharma Francis Srl | CO-CRYSTAL AND AMORPHOUS FORM OF AN ANTI-DIABETIC DRUG |
WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2022208172A1 (en) | 2021-04-01 | 2022-10-06 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Also Published As
Publication number | Publication date |
---|---|
CA2444481A1 (en) | 2002-10-24 |
ES2258141T3 (en) | 2006-08-16 |
CY1105038T1 (en) | 2010-03-03 |
WO2002083066A3 (en) | 2003-03-06 |
HUP0600232A2 (en) | 2006-08-28 |
EP1385856A4 (en) | 2005-05-11 |
DK1385856T3 (en) | 2006-05-15 |
EP1385856B1 (en) | 2006-02-22 |
DE60209343D1 (en) | 2006-04-27 |
US6774112B2 (en) | 2004-08-10 |
AU2002254567B2 (en) | 2007-10-11 |
JP2004536047A (en) | 2004-12-02 |
US20030064935A1 (en) | 2003-04-03 |
ATE318272T1 (en) | 2006-03-15 |
EP1385856A2 (en) | 2004-02-04 |
DE60209343T2 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002254567B2 (en) | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method | |
AU2002254567A1 (en) | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method | |
EP1224195B1 (en) | C-aryl glucoside sglt2 inhibitors | |
US6936590B2 (en) | C-aryl glucoside SGLT2 inhibitors and method | |
US6515117B2 (en) | C-aryl glucoside SGLT2 inhibitors and method | |
US20030087843A1 (en) | O-pyrazole glucoside SGLT2 inhibitors and method of use | |
EP1268502A1 (en) | O-aryl glucoside sglt2 inhibitors and method | |
AU2001249598A1 (en) | O-aryl glucoside sglt2 inhibitors and method | |
AU2001249599A1 (en) | O-glucosylated benzamide sglt2 inhibitors and method | |
AU2008200159A1 (en) | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002254567 Country of ref document: AU Ref document number: 2444481 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002580871 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002723801 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002723801 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002723801 Country of ref document: EP |